With the business potentially at an important milestone, we thought we'd take a closer look at RenovoRx, Inc.'s (NASDAQ:RNXT) future prospects. RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. The US$39m market-cap company posted a loss in its most recent financial year of US$11m and a latest trailing-twelve-month loss of US$12m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is RenovoRx's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Consensus from 4 of the American Biotechs analysts is that RenovoRx is on the verge of breakeven. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$5.7m in 2028. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 73% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving RenovoRx's growth isn’t the focus of this broad overview, but, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one aspect worth mentioning. RenovoRx currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of RenovoRx to cover in one brief article, but the key fundamentals for the company can all be found in one place – RenovoRx's company page on Simply Wall St. We've also put together a list of important aspects you should look at:

1. Valuation: What is RenovoRx worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether RenovoRx is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on RenovoRx’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.